Blood and BM Path Chapters 20-21 - MDS and MDS/MPN Flashcards
Diagnostic flow diagram in suspected MPN
The bone marrow in MDS is usually ____
The bone marrow in MDS is usually hypercellular
It is characterized by ineffective hematopoiesis, not asplasia
Defining features of MDS with refractory anemia/thrombocytopenia/neutropenia
Dyshematopoiesis in one, two, or all three lineages. (If 2 or more linages, diagnosed as “with multilineage dysplasia”)
<5% bone marrow blasts.
<1% peripheral blasts.
Not meeting criteria for another category.
Defining features of MDS with refractory anemia and ringed sideroblasts
Dyshematopoiesis in erythrocytes.
<5% bone marrow blasts.
<1% peripheral blasts.
Ringed sideroblasts comprising >15% of bone marrow erythroblasts
Defining features of MDS with excess blasts
Dyshematopoiesis in one, two, or all three lineages.
EB stage I: 5-9% blasts in the bone marrow and <5% circulating blasts
EB stage II: 10-19% blasts in the bone marrow or >5% circulating blasts or Auer rods in a blast
If dysplasia is present, >20% BM blasts automatically puts you in AML with myelodysplastic features
Defining features of CMML
Meeting criteria for any diagnosis of myelodysplastic syndrome
plus
> 1 × 109/L absolute monocytes/promonocytes in peripheral blood
“Minimum” diagnostic criteria for MDS
Evidence of dysplasia in >10% of cells of a given lineage in the bone marrow, in the appropriate clinical context
Translocations and diagnosis of MDS vs AML with myelodysplastic features
The holy trinity of hematology, t(15:17), inv(16)/t(16;16), and t(8;21) automatically get a diagnosis of AML irrespective of their blast count.
Any other translocation, including t(9;11), t(6;9), inv(3)/t(3;3), and t(1;22), still need to meet the >20% bone marrow or circulating blasts criterion to qualify as AML. Otherwise, these are diagnosed as MDS with recurrent genetic anomalies. However, they may become a diagnosis of AML on 2 month follow-up biopsies.
MDS with del(5q)
Form of MDS with recurrent genetic anomalies
Usually associated with anemia, but normal or even increased platelet count. No or rare blasts in BM.
BM will have normal to increased number of megakaryocytes, but significant megakaryocyte dysplasia with monolobed nuclei is typically present.
This phenotype is due to loss of RPS14, ribosomal protein S14, a component of the 40S ribosome. Selective loss of this gene also produces this phenotype.
Autoimmunity in patients with MDS
~10% of patients with MDS have or develop comorbid autoimmune conditions
The TSG interferon regulatory factor-1 (IRF-1) has been linked to this phenomenon. It is frequently overexpressed in MDS, and high expression predisposes to autoimmunity.
Elevated serum __ is a poor prognostic factor for MDS
Elevated serum LDH is a poor prognostic factor for MDS
DDx for dysgranulopoiesis
- GCSF / GMCSF therapy
- Viral infections (HIV, EBV)
- Paraneoplastic condition
- Immediately post-chemotherapy
-
Drug-induced
- Bactrim
- Mofetil
- Clozapine
- Methimazole
- Prophythiouracil
- Dapsone
- Beta lactams
- NSAIDs
- Anticonvulsants
DDx for dysmegakaryocytosis
Infections (HIV)
Myelofibrosis (paraneoplastic or autoimmune)
Post-transplant
Post-chemotherapy
Best staining method to evaluate for MDS
Giemsa-Wright
This allows you to see both granulation in neutophils and basophilic stippling in red cells.
Sideroblastic anemia as a “microcytic anemia”
Many textbooks list it this way, but this only applies for hereditary or lead-induced sideroblatic anemia – NOT MDS